Tatsuki Fukami


Affiliation: Kanazawa University
Country: Japan


  1. Ogiso T, Fukami T, Mishiro K, Konishi K, Jones J, Nakajima M. Substrate selectivity of human aldehyde oxidase 1 in reduction of nitroaromatic drugs. Arch Biochem Biophys. 2018;659:85-92 pubmed publisher
    ..In conclusion, this provides new information related to the substrate selectivity of human AOX1 for the reduction of nitroaromatic drugs. ..
  2. Konishi K, Fukami T, Ogiso T, Nakajima M. In vitro approach to elucidate the relevance of carboxylesterase 2 and N-acetyltransferase 2 to flupirtine-induced liver injury. Biochem Pharmacol. 2018;155:242-251 pubmed publisher
    ..NAT2 slow acetylators with high CES2 activity could be highly susceptible to flupirtine-induced liver injury. ..
  3. Fukami T, Kariya M, Kurokawa T, Iida A, Nakajima M. Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases. Eur J Pharm Sci. 2015;78:47-53 pubmed publisher
    ..The role of AADAC in the hydrolysis of drugs has been clarified. For this reason, AADAC should receive attention in ADMET studies during drug development. ..
  4. Kurokawa T, Fukami T, Nakajima M. Characterization of Species Differences in Tissue Diltiazem Deacetylation Identifies Ces2a as a Rat-Specific Diltiazem Deacetylase. Drug Metab Dispos. 2015;43:1218-25 pubmed publisher
    ..The characterization of Ces enzymes in animal species, as undertaken in this study, will prove useful to predict the species-specific pharmacokinetics differences between the in vivo models used for drug development. ..
  5. Sasaki E, Iwamura A, Tsuneyama K, Fukami T, Nakajima M, Kume T, et al. Role of cytochrome P450-mediated metabolism and identification of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury. Toxicol Lett. 2015;232:79-88 pubmed publisher
    ..These findings suggest that the arene oxide intermediate, which can be converted to thiol conjugates, is involved in DPH-induced liver injury. ..
  6. Sasaki E, Iida A, Oda S, Tsuneyama K, Fukami T, Nakajima M, et al. Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors. Exp Toxicol Pathol. 2016;68:27-38 pubmed publisher
    ..Hepatic adenosine triphosphate (ATP) contents were significantly decreased 24 h after CBZ administration. Therefore, the Kupffer cells-mediated inflammation was predominant in the development of the CBZ-induced liver injury in rats. ..
  7. Muta K, Fukami T, Nakajima M. A proposed mechanism for the adverse effects of acebutolol: CES2 and CYP2C19-mediated metabolism and antinuclear antibody production. Biochem Pharmacol. 2015;98:659-70 pubmed publisher
    ..These results suggested that the hydrolysis and oxidation of acebutolol was associated with ANA production. In summary, this study demonstrated that metabolic activation may be a causal factor of adverse reactions of acebutolol. ..
  8. Kurokawa T, Fukami T, Yoshida T, Nakajima M. Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog. Drug Metab Dispos. 2016;44:409-16 pubmed publisher
    ..Collectively, we found that AADAC largely contributes to prasugrel hydrolysis in both human and dog intestine. ..
  9. Amano T, Fukami T, Ogiso T, Hirose D, Jones J, Taniguchi T, et al. Identification of enzymes responsible for dantrolene metabolism in the human liver: A clue to uncover the cause of liver injury. Biochem Pharmacol. 2018;151:69-78 pubmed publisher
    ..In conclusion, we found that AOX1 and NAT2 were responsible for dantrolene metabolism in humans and that AOX1-dependent metabolism determines dantrolene-induced liver injury. ..

More Information


  1. request reprint
    Fukami T, Yokoi T. The emerging role of human esterases. Drug Metab Pharmacokinet. 2012;27:466-77 pubmed
    ..Further esterase studies should be conducted to promote our understanding in clinical pharmacotherapy and drug development. ..
  2. Muta K, Fukami T, Nakajima M, Yokoi T. N-Glycosylation during translation is essential for human arylacetamide deacetylase enzyme activity. Biochem Pharmacol. 2014;87:352-9 pubmed publisher
    ..Overall, this study found that the translational, but not post-translational, N-glycosylation of AADAC plays a crucial role in regulating AADAC enzyme activity. ..
  3. Fukami T, Iida A, Konishi K, Nakajima M. Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity. Biochem Pharmacol. 2016;116:153-61 pubmed publisher
    ..Cytotoxicity of KC in human primary hepatocytes was attenuated by diisopropylfluorophosphate, an AADAC inhibitor. In conclusion, the present study demonstrated that human AADAC hydrolyzes KC to trigger hepatocellular toxicity. ..
  4. Yoshida T, Fukami T, Kurokawa T, Gotoh S, Oda A, Nakajima M. Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans. Eur J Pharm Sci. 2018;111:167-176 pubmed publisher
    ..In conclusion, the present study could provide new finding to facilitate our understanding of species differences in drug hydrolysis, which can facilitate drug development and drug safety evaluation. ..
  5. Ito Y, Fukami T, Yokoi T, Nakajima M. An orphan esterase ABHD10 modulates probenecid acyl glucuronidation in human liver. Drug Metab Dispos. 2014;42:2109-16 pubmed publisher
    ..The balance of activities by these enzymes is important for the formation of PRAG, which may be associated with the adverse reactions observed after probenecid administration. ..
  6. Konishi K, Fukami T, Gotoh S, Nakajima M. Identification of enzymes responsible for nitrazepam metabolism and toxicity in human. Biochem Pharmacol. 2017;140:150-160 pubmed publisher
    ..In sum, we found that AOX1, NAT2, AADAC, and CYP3A4 are the determinants for the pharmacokinetics of NZP and that they confer interindividual variability in sensitivity to NZP side effects. ..